Related Experiment Video
Updated: Jul 23, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Cognitive impairment in opioid use disorders: Is there a case for use of nootropics?
Gayatri Bhatia1, Ragul Ganesh2, Alok Kulkarni3
1Department of Psychiatry, All India Institute of Medical Sciences, Rajkot, India.
Abstract:
Opioid Use Disorders (OUDs) are often associated with cognitive impairments, which may lead to an increased risk of relapse. These cognitive deficits do not resolve with abstinence or medication-assisted treatment and may require targeted management. While psychotherapies and neuromodulation techniques have been studied for their effectiveness, they have certain limitations and challenges. Cognition enhancing prescription drugs like donepezil and memantine, which are used in dementias, have shown promise in a small number of studies examining their role in the reversal of opioid-induced cognitive deficits. The authors explore the potential role of nootropics in improvement of cognitive decline associated with OUDs.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...

